

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00455)

**POLL RESULTS OF ANNUAL GENERAL MEETING;
RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR;
APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR;
AND
CHANGE IN COMPOSITION OF BOARD COMMITTEES**

POLL RESULTS OF THE AGM

Tianda Pharmaceuticals Limited (the “**Company**”) is pleased to announce the poll results in respect of the resolutions proposed at the annual general meeting of the Company held on 27 June 2023 (the “**AGM**”) as follows:

ORDINARY RESOLUTIONS ^(NOTE)		Number of Votes (%)	
		For	Against
1.	To receive and consider the audited consolidated financial statements, the report of the Directors and the independent auditor’s report for the nine months ended 31 December 2022.	1,707,717,908 (100%)	0 (0%)
2.	To declare a final dividend of HK0.26 cent per share.	1,707,717,908 (100%)	0 (0%)
3.	(a) To re-elect Mr. Lui Man Sang as an Executive Director.	1,707,717,908 (100%)	0 (0%)
	(b) To re-elect Mr. Lam Yat Fai (who has served as an Independent Non-executive Director for more than 9 years) as an Independent Non-executive Director.	1,707,717,908 (100%)	0 (0%)
	(c) To re-elect Mr. Chiu Sung Hong (who has served as an Independent Non-executive Director for more than 9 years) as an Independent Non-executive Director.	1,707,717,908 (100%)	0 (0%)
	(d) To authorise the Board of Directors to fix the Directors’ remuneration for the year ending 31 December 2023.	1,707,717,908 (100%)	0 (0%)
4.	To re-appoint Ernst & Young as auditor of the Company and to authorise the Board of Directors to fix the remuneration of auditor.	1,707,717,908 (100%)	0 (0%)
5.	To grant a general mandate to the Directors to repurchase shares of the Company.	1,707,717,908 (100%)	0 (0%)

ORDINARY RESOLUTIONS ^(NOTE)		Number of Votes (%)	
		For	Against
6.	To grant a general mandate to the Directors to allot and issue new shares of the Company.	1,707,717,908 (100%)	0 (0%)
7.	To extend the general mandate granted to allot and issue new shares by adding the shares repurchased by the Company.	1,707,717,908 (100%)	0 (0%)
SPECIAL RESOLUTION ^(NOTE)		Number of Votes (%)	
		For	Against
8	To approve the proposed amendments to the memorandum of association of the Company (the “Existing Memorandum”) and the amended and restated articles of association of the Company (the “Existing Articles”) and the adoption of the amended and restated memorandum of association of the Company and the second amended and restated articles of association of the Company in substitution for and to the exclusion of the Existing Memorandum and the Existing Articles	1,707,717,908 (100%)	0 (0%)

Note: Please refer to the notice of AGM of the Company dated 24 May 2023 for the full text of the resolutions.

As more than 50% of the votes were cast in favour of the above ordinary resolutions numbered 1 to 7, all the ordinary resolutions were duly passed.

As more than 75% of the votes were cast in favour of the above special resolution numbered 8, the special resolution was duly passed.

As at the date of the AGM, the total number of issued and fully paid up shares of the Company was 2,150,041,884 shares. In relation to all resolutions proposed at the AGM, the total number of shares entitling the holders to attend and vote for or against the resolutions at the AGM was 2,150,041,884 shares. There were no shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and there were no shares requiring the holders to abstain from voting at the AGM under the Listing Rules.

The AGM was convened by the Board and chaired by Mr. FANG Wen Quan, the Chairman and Managing Director of the Company. All Directors of the Company attended the AGM in person or by electronic means except Mr. FENG Quanming.

Tricor Secretaries Limited, the Hong Kong Branch Share Registrar of the Company, acted as scrutineer for the poll at the AGM.

Shareholders may refer to the circular dated 24 May 2023 (the “**Circular**”) for details of the above resolutions proposed at the AGM. The Circular may be viewed and downloaded from the Company’s website at www.tiandapharma.com or the designated website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk.

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board hereby announces that Mr. CHIU Fan Wa (“**Mr. CHIU**”) has tendered resignation as an Independent Non-executive Director with effect from 1 July 2023 as he has decided to devote more time to his personal matters. Mr. CHIU has confirmed that he does not have any disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board expresses its sincere gratitude to Mr. CHIU for his valuable contributions to the Company during his tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board further announces that after the AGM, Dr. XIAN Yanfang (“**Dr. XIAN**”) has been appointed as an Independent Non-executive Director with effect from 27 June 2023. The biographical details of Dr. XIAN is set out below:

Dr. Xian Yanfang, aged 42, is an assistant professor of School of Chinese medicine, The Chinese University of Hong Kong. She has extensive research experience in the field of Pharmacology of Chinese medicines, Herb-drug interactions of Chinese and western medicines and Quality control of Chinese medicines. Dr. Xian is currently a project review expert of National Natural Science Foundation of China, the general secretary of Hong Kong Association of Chinese Herbal Pharmacology, a member of technical support team in Pharmacology and Toxicology of The Hong Kong Government Chinese Medicines Testing Institute, the committee member of Deficiency Syndrome and Geriatrics Professional Committee of China Association of Integrative Medicine, and a member of Branch of Integrative Traditional Chinese and Western Medicine of the China Association of Gerontology and Geriatrics.

Dr. Xian holds a Ph.D degree in Chinese Medicine from The Chinese University of Hong Kong, and a master’s degree and a bachelor’s degree in Science of Chinese Materia Medica from Guangzhou University of Chinese Medicine.

Save as disclosed above, as of the date of this announcement, Dr. XIAN (i) has not held any directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (ii) does not have any relationship with any directors, supervisors, senior management, or substantial or controlling shareholder of the Company; (iii) does not hold any other positions in the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Dr. XIAN has entered into an appointment letter with the Company for an initial term of two years commencing from 27 June 2023, subject to retirement by rotation and re-election at the next annual general meeting in accordance with the articles of association of the Company. Dr. XIAN is entitled to receive emoluments of HK\$72,000 per annum. Save as disclosed above, the Board is not aware of any matter in relation to Dr. XIAN that is required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange or any other matters that need to be brought to the attention of the Shareholders and the Stock Exchange in relation to her appointment.

The Board would like to take this opportunity to express its warmest welcome to Dr. XIAN.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board further announces that Dr. XIAN is appointed as a member of each of the audit committee and remuneration committee of the Company following her appointment as Independent Non-executive Director of the Company on 27 June 2023; and Mr. CHIU will cease to be a member of each of the audit committee and remuneration committee of the Company following his resignation as Independent Non-executive Director of the Company on 1 July 2023.

For and on behalf of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 27 June 2023

As at the date of this announcement, the Executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the Non-executive Directors are Mr. SHEN Bo and Mr. FENG Quanming; and the Independent Non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong, Mr. CHIU Fan Wa and Dr. XIAN Yanfang.